Clinical trials: Amplification
Solid Tumor
Study to Evaluate the Safety and Efficacy of Gefitinib, in Subjects With EFGR Amplification Refractory Solid Tumors
This study is a single-arm,phase II study of gefitinib in patient with epidermal growth factor receptor amplification Refractory solid tumors. Gefitinib 250 mg will be administered orally daily.
- Trial name
- NCT02447419
- Testing
- Gefitinib
- Where
- South Korea
- Volunteers
- 16 people
- Sponsor
- Samsung Medical Center
Influenza
Evaluation of the Alere i Influenza A&B Nucleic Acid Amplification Versus Xpert Flu/RSV
The rapid and accurate detection of influenza virus in respiratory specimens is required for optimal management of patients with acute respiratory infections.
- Trial name
- NCT02846311
- Testing
- Flu Test
- Where
- France
- Volunteers
- 92 people
- Sponsor
- Fondation Hôpital Saint-Joseph
Tuberculosis Diagnosis
Evaluation of New TB Diagnostic Tests (NATs) in Pakistan
This study evaluates two portable molecular tests for tuberculosis (TB), Pluslife MTBC and Ustar PortNAT, during community-based active case-finding activities in Pakistan.
- Trial name
- TB (NCT06984887)
- Testing
- Paired tongue-swab and sputum-based molecular testing for tuberculosis
- Where
- 2 sites in Pakistan
- Volunteers
- 6,100 people, healthy volunteers welcome
- Sponsor
- Mercy Corps Pakistan
Sexually Transmitted Diseases
Utility and Acceptability of a Molecular Test in the Management of Sexually Transmitted Diseases in Uganda
The goal of this clinical trial is to assess utility and acceptability of a molecular test in comparison with clinical syndromic approach in the management of sexually transmitted diseases (STD) at STD clinic of Mulago National…
- Trial name
- ASTRHA (NCT05994495)
- Testing
- nuclear acid amplification tests, Clinical Syndromic Approach
- Where
- Uganda
- Volunteers
- 220 people
- Sponsor
- Riccardo Serraino
Carcinoma, Non-Small-Cell Lung
Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)
Study to evaluate the efficacy and safety of capmatinib as a single-agent treatment for subjects with advanced/metastatic (stage IIIB or IV) non-small cell lung cancer (NSCLC) who had wild-type epidermal growth factor receptor…
- Trial name
- NCT02414139
- Testing
- Capmatinib
- Where
- 95 sites in United States, Argentina and 18 more
- Volunteers
- 373 people
- Sponsor
- Novartis Pharmaceuticals
HER2 Mutant Non-small Cell Lung Cancer, HER2-positive Metastatic Breast Cancer
ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer
The goal of this clinical trial is to test ELVN-002 in people with cancers that have an abnormal HER2 gene. The main question the trial aims to answer is if ELVN-002 is safe and tolerable at different doses.
- Conditions
- HER2 Mutant Non-small Cell Lung Cancer, HER2-positive Metastatic Breast Cancer, HER2 Gene Mutation, HER2 Amplification
- Trial name
- HER2 (NCT05650879)
- Testing
- ELVN-002, Fam-Trastuzumab Deruxtecan-Nxki, Trastuzumab emtansine
- Where
- 39 sites in United States, Australia and 5 more
- Volunteers
- 198 people
- Sponsor
- Enliven Therapeutics
Preimplantation Diagnosis
Feasibility Study of Preimplantation Genetic Diagnosis for Single-gene Disorders
Preimplantation Genetic Diagnosis (PGD) for monogenic diseases is usually performed by multiplex PCR combining polymorphic microsatellites familial analysis and, where possible, couple-specific mutation detection.
- Trial name
- NCT02502214
- Where
- France
- Volunteers
- 30 people
- Sponsor
- University Hospital, Strasbourg, France
HER-2 Gene Amplification
A Study of MM-111 in Combination With Multiple Treatments in Patients With HER2 Positive Cancer
This study is an open-label, dose-escalation study of MM-111 with five different combination treatments with the main goal of determining the safety of MM-111 with each combination.
- Trial name
- NCT01304784
- Testing
- Cisplatin, Capecitabine, Trastuzumab and MM-111, Lapatinib +/- Trastuzumab and MM-111, Paclitaxel, Trastuzumab and MM-111
- Where
- 15 sites in United States
- Volunteers
- 100 people
- Sponsor
- Merrimack Pharmaceuticals
FGFR1 Gene Amplification, FGFR1 Gene Mutation
Pemigatinib for the Treatment of Metastatic or Unresectable Colorectal Cancer Harboring FGFR Alterations
This phase II trial studies how well pemigatinib works in treating patients with colorectal cancer with mutations (alterations) in a FGFR gene and that has spread to other places in the body (metastatic) or cannot be removed by…
- Conditions
- FGFR1 Gene Amplification, FGFR1 Gene Mutation, FGFR1 Gene Translocation, FGFR2 Gene Amplification
- Trial name
- NCT04096417
- Testing
- Pemigatinib, Quality-of-Life Assessment
- Where
- 6 sites in United States
- Volunteers
- 14 people
- Sponsor
- Academic and Community Cancer Research United
Chlamydia, Gonorrhea
Detection of Chlamydia (CT) and Gonorrhea (NG)
To evaluate the illumigene Chlamydia and illumigene Gonorrhea assays, using the illumipro-10, with male urine, female urine, physician-collected (medical professional) endocervical swabs and self-collected vaginal swabs taken…
- Trial name
- NCT02055742
- Testing
- illumigene CT and NG assays, illumipro-10
- Where
- 3 sites in United States
- Volunteers
- 700 people, healthy volunteers welcome
- Sponsor
- Meridian Bioscience, Inc.
Glioblastoma, Glioblastoma, IDH-Wildtype
ERAS-801 for the Treatment of Resectable and Progressive or Recurrent or Elderly Newly Diagnosed IDH Wildtype Grade IV Glioblastoma or Gliosarcoma With an EGFR Amplification or Mutation, ERAS801-SARG Trial
This phase Ib trial tests the safety and side effects of ERAS-801 in treating patients with isocitrate dehydrogenase (IDH) wildtype, epidermal growth factor receptor (EGFR) amplified or mutated grade IV glioblastoma or…
- Conditions
- Glioblastoma, Glioblastoma, IDH-Wildtype, Gliosarcoma, Recurrent Glioblastoma, IDH-Wildtype
- Trial name
- NCT07089641
- Testing
- Biospecimen Collection, Echocardiography Test, EGFR Inhibitor ERAS-801
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Polyomavirus
Amplification of Merkel Cell Polyomavirus From Skin Swabs
Background: Polyomavirus are DNA-based viruses that infect vertebrates, including humans. Most people are not harmed by polyomavirus infection, but people with compromised immune systems may be harmed by these viruses, and are at…
- Trial name
- NCT00977990
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Glioblastoma, Gliosarcoma
Study of ABBV-637 or ABBV-155 With ERAS-801 for People With Glioblastoma
The researchers are doing this study to find out whether the drugs ABBV-637 and ABBV-155 are safe treatments that cause few or mild side effects when given alone or in combination with ERAS-801 in people with recurrent GBM.
- Trial name
- NCT06934889
- Testing
- ERAS-801, ABBV-637, ABBV-155
- Where
- 11 sites in United States
- Volunteers
- 60 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Solid Tumors Harboring NTRK Fusion, NTRK
A Phase 1/2 Study of CG001419 Tablets in Adult Subjects With Locally Advanced or Metastatic Solid Tumours Harbouring NTRK Gene Abnormalities
The goal of this clinical trial is to learn about the safety of drug CG001419. It also learn if drug CG001419 works to treat in locally advanced/metastatic adult solid tumours with NTRK gene fusions, NTRK gene point mutations…
- Conditions
- Solid Tumors Harboring NTRK Fusion, NTRK, NTRK Gene Fusion, NTRK Fusion Positive
- Trial name
- NCT07394374
- Testing
- CG001419 tablets
- Where
- 6 sites in China
- Volunteers
- 42 people
- Sponsor
- Cullgen (Shanghai),Inc
COVID-19, Kidney Injury
Morphofunctional, Gene, Inflammation Molecules and Oxidative Stress Analysis in Kidney Tissue of COVID-19 Patients
The involvement of the kidneys in patients infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at the outset of the pandemic was associated with high mortality rates worldwide.
- Conditions
- COVID-19, Kidney Injury, Gene Amplification, Oxidative Stress
- Trial name
- NCT06444893
- Where
- Mexico
- Volunteers
- 40 people
- Sponsor
- Instituto Nacional de Enfermedades Respiratorias
Haematological Malignancy, Colorectal Neoplasms
DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating Mutations
This clinical trial is looking at a combination of drugs called trastuzumab and pertuzumab. This combination of drugs is approved together as standard of care treatment for adult patients with breast cancer (often with other…
- Conditions
- Haematological Malignancy, Colorectal Neoplasms, Urinary Bladder Neoplasm, Gallbladder Neoplasms
- Trial name
- DETERMINE (NCT05786716)
- Testing
- Trastuzumab, Pertuzumab
- Where
- 27 sites in United Kingdom
- Volunteers
- 30 people
- Sponsor
- Cancer Research UK
Diabetic Retinopathy
Circadian Amplification in Diabetic Retinopathy
This study will test the effects of a 6-week comprehensive circadian optimization intervention Amplify-RHYTHM in patients with diabetic retinopathy.
- Trial name
- NCT06183476
- Testing
- Amplify-RHYTHM
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- University of Illinois at Chicago
Low Grade Upper Tract Urothelial Carcinoma
Phase 2A/B Efficacy and Safety of Dabogratinib in Participants With Low Grade Upper Tract Urothelial Carcinoma
A Phase 2A/B study of Dabogratinib (TYRA-300) in Low Grade Upper Tract Urothelial Carcinoma
- Trial name
- SURF303 (NCT07265947)
- Testing
- Dabogratinib (TYRA-300) 60mg, Dabogratinib (TYRA-300) 80mg
- Where
- 32 sites in United States, France and 2 more
- Volunteers
- 285 people
- Sponsor
- Tyra Biosciences, Inc
Urothelial Carcinoma
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
This study is being done to see if a drug called disitamab vedotin, alone or with pembrolizumab, works to treat HER2 expressing urothelial cancer. It will also test how safe the drug is for participants.
- Trial name
- NCT04879329
- Testing
- disitamab vedotin, pembrolizumab
- Where
- 221 sites in United States, Argentina and 10 more
- Volunteers
- 372 people
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
Carcinoma, Transitional Cell, HER-2 Gene Amplification
A Study of Trastuzumab and Pyrotinib in HER2 Positive Locally Advanced or Metastatic Urothelial Carcinoma
A open-label, single-arm, phase II trial to study was designed to evaluate the effectiveness and safety of trastuzumab and pyrotinib in treating HER2 positive patients who have previously treated, locally advanced, or metastatic…
- Trial name
- NCT05318339
- Testing
- Trastuzumab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Chinese Academy of Medical Sciences